Brexanolone(CAS516-54-1) PPD treatment,Anxiolytic Steroids

Brexanolone, sold under the brand name Zulresso, is a breakthrough intravenous medication specifically approved for the treatment of postpartum depression (PPD) in adults. As a synthetic form of allopregnanolone—a naturally occurring neurosteroid—it works as a positive allosteric modulator of $GABA_A$ receptors. By rapidly restoring GABA signaling, which often fluctuates dramatically after childbirth, Brexanolone helps rebalance brain chemistry. Clinical trials have demonstrated that it provides rapid-acting and significant reduction in depressive symptoms, with many patients experiencing noticeable improvement within 48 hours of starting the 60-hour infusion.